XENE - This Analyst Is Bullish On Biohaven's Approach in Neuro-Psych Space | Benzinga
RBC Capital Markets has initiated Biohaven Ltd (NYSE:BHVN), noting optimized development across programs.
The analyst highlights the company’s way of identifying promising technologies and targets and leveraging its management expertise to optimize the development path based on competitor data to become a fast follower in high-value therapeutic areas.
RBC analyst says the Kv7 modulators are an exciting new mechanism in the neuro-psych space with a blockbuster potential of $3.2 billion across epilepsy and mood disorders and, like Biohaven’s approach of leveraging learnings from competitor Xenon Pharmaceuticals Inc (NASDAQ:XENE) to accelerate its development path.
RBC has initiated Biohaven with an Outperform, Speculative Risk rating, and a price ...